Identification of DCAF5 as a novel cancer prognostic and immunotherapy biomarker through pan-cancer analysis and renal clear cell carcinoma clinical data validation

Abstract Background: DCAF5 encodes a component of ubiquitin ligase complex, thereby influencing protein ubiquitination. Recent research underscored its potential to revert the malignant phenotype, as evidenced in vivo studies, while the scarcity of research about DCAF5 challenges for its development as a novel target for cancer treatment. Methods: We conducted an immunohistochemical analysis to compare the expression levels of DCAF5 in renal clear cell carcinoma tissues with those in adjacent non-neoplastic tissues. Subsequently, we performed survival analyses to explore the